Investors

Vicore Pharma Holdings share is listed on NASDAQ First North since December 10, 2015

Share information
  • Ticker symbol for First North: VICO
  • ISIN-code: SE0007577895
  • The shares are registrered by securities depository, Euroclear Sweden AB.

Important information about Nasdaq Stockholm First North

Companies whose shares are traded on First North are not required to follow the same rules as companies whose shares are traded on the regulated main market; instead they use a less extensive rulebook than the main market, which is adapted for smaller growth companies.An investment in a company whose shares are traded on First North may therefore carry more risk than an investment in a company whose shares are traded on a regulated market. All companies whose shares are traded on First North have a Certified Adviser to ensure they comply with all requirements and rules for disclosure of information to the market and investors. A Certified Adviser monitors the company whose shares will be listed for trading on First North, and NASDAQ approves such an application for listing.

Development of share capital

YearEventQuota valueIncrease in number of sharesIncrease in share capitalTotalt number of sharesTotal share capital
2005Formation1001 000100 000,001 000100 000,00
2008Bonus issue1004 601460 100,005 601560 100,00
2008Breakdown of shares 1:20000,0511 196 399-11 202 000560 100,00
2008Share issue0,0568834,411 202 688560 134,40
2010Share issue0,055 601 344280 067,2016 804 032840 201,60
2010Share issue0,055 601 344280 067,2022 405 3761 120 268,80
2010Set-off issue0,051 000 00050 000,0023 405 3761 170 268,80
2011Share issue0,0510 402 389520 119,4533 807 7651 690 388,25
2012Set-off issue0,05474 49823 724,9034 282 2631 714 113,15
2013Share issue0,0534 282 2631 714 113,1568 564 5263 428 226,30
2015Share issue0,0512 639 073631 953.6581 203 5994 060 179,95
2015reversed split 1:100,5-73 083 239-8 120 3604 060 180,00
2015Share issue/Listing0,53 248 1441 624 07212 368 5045 684 252,00
2017Share issue0,52 000 0001 000 00014 368 5047 184 251,92
2017Share issue0,51 500 000750 00015 868 5047 934 251,92
2018Issue in kind0,58 851 5024 425 750,9624 720 00612 360 002,88
2018Share issue0,58 240 0024 120 000,9632 960 00816 480 003,83

Shareholders

November 19, 2018

ShareholderNr of shares%
Total nr of shares
32 960 008100%
HealthCap VII L.P.10 031 70230,4%
Protem Wessman incl. private
3 526 849
10.7%
Swedbank Robur
2 093 3326.4%
Kjell Stenberg
1 531 303
4.6%
HBM Healthcare Investments (Cayman) Ltd
1 362 791
4,1%
Pomona-gruppen AB
1 074 440
3.3%
Unionen
1 038 9903,2%
Eriksam Invest AB incl. private
759 8332.3%
Mikael Lönn
598 478
1.8%
Carl-Johan Dalsgaard477 9811.4%
Other10 464 30931,7%

Financial

Calendar

Year-end report

22 February 2019

Annual report 2018

12 April 2019

Interim report, Q1

15 May 2019

Interim report, Q2

23 August 2019

Interim report, Q3

18 October 2019

Events &

Presentations

w
Previous events & presentations

Pareto Securities Healthcare conference
Stockholm, 6 september 2018
www.paretosec.com/conferences.php

Småbolagsdagen 2018 (SWE)
Company Presentation
Stockholm, 11 June 2018

Biotech and Money Investival showcase
London, November 14, 2017

Jefferies Healthcare conference
London, November 15-16, 2017

Bolagsdagen (Company presentations), Erik Penser bank
Stockholm, November 23 2017

Stora aktiedagen (Swedish shareholders meet)
Göteborg, November 27, 2017

Audiocast/Conference call
Presentation of results from extension study
October 2, 2017 at 14:00 CET

BIO International Convention
San Diego, June 19-20, 2017

Jefferies Health Care Conference
New York, June 6-9, 2017

Per Jansson, CEO presents Vicore Pharma on event with Redeye on May 4, 2017
Early-bird company presentation, may 4, 2017

Interview with Per Jansson, CEO at Vicore Pharma:
CEO interview, april 10, 2017

Per Jansson, CEO presents Vicore Pharma on Stora aktiedagen in Gothenburg on november 14, 2016:

Company presentation november 14

Per Jansson, CEO presents Vicore Pharma on event with Aktiespararna in Stockholm on March 8, 2016:
Company presentation march 8, 2016

Per Jansson, CEO presents Vicore Pharma on Stora aktiedagen in Gothenburg on November 23 2015:
Company presentation November 23>>

Björn Dahlöf, Senior Medical Advisor presents Vicore Pharma on event with Redeye in Gothenburg on November 3, 2015:
Company presentation November 3>>

Per Jansson, CEO presents Vicore Pharma on event with Aktiespararna in Stockholm on october 19, 2015:
Company presentation October 19>>

Dawid Myslinski, Corporate Finance on Redeye talks about Vicore Pharma:
Dawid Myslinski on Vicore Pharma

Analysts

Brigitte de Lima
goetzpartners securities Limited

goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG

Dir: +44 (0)203 897 6663
E-mail: brigitte.delima@goetzpartners.com
Web: www.goetzpartnerssecurities.com

goetzpartners Research – Vicore Pharma AB – company note – 13 December 2018

goetzpartners Research – Vicore Pharma AB – flash note – 5 September 2018

goetzpartners Research – Vicore Pharma AB – flash note – 3 July 2018

goetzpartners Research – Vicore Pharma AB – initiation report – 22 March 2018

 

Disclaimer
These research reports are intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Vicore Pharma is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Vicore Pharmas performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vicore Pharma or its management. Vicore Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Incentive programmes

Incentive programme

On January 8, 2016, Vicore Pharma Holding issued 570 000 warrants to key employees and key researchers. The increase in the Company’s share capital in full exercise of the warrants will amount to SEK 285 000, which corresponds to a dilution of 2.3 percent of the total number of shares and of the total number of votes in the company.

At the Extraordinary General Meeting on August 13, it was resolved to implement two new incentive programs: a maximum of 2,000,000 warrants to senior leaders and key persons (”Co-worker LTIP 2018”); and a maximum of 475,000 share awards to board members (”Board LTIP 2018”). The increase in the Company’s share capital in full utilization of both incentive programs amounts to a maximum of approximately SEK 1 237 500, corresponding to a dilution of 9.2 percent of the total number of shares.

During the period, 300,000 options were granted to senior managers and key employees in accordance with Co-worker LTIP 2018.

 

If you have any questions as an investor, please contact us!

Carl-Johan Dalsgaard, CEO 
carl-johan.dalsgaard@vicorepharma.com
Tel: +46 709 75 98 63

Hans Jeppsson, CFO
hans.jeppsson@vicorepharma.com
Tel: +46 705 53 14 65

Nina Carlén, IR, Communication and Administration coordinator
nina.carlen@vicorepharma.com
M: +46 763 90 94 04

Certified Advisor
Erik Penser Bank AB
Apelbergsgatan 27
Box 7405
103 91 Stockholm, Sweden
T: +46 8 463 8000